

Global Antibody Drug Conjugates Market Set For 23.4% Growth, Reaching \$24.8 Billion By 2028

The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!

LONDON, GREATER LONDON, UNITED KINGDOM, December 18, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



The Business
Research Company

Antibody Drug Conjugates Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033

[The antibody drug conjugates market size has experienced significant growth](#) over the recent years. It is expected to upsurge from \$8.78 billion in 2023 to \$10.7 billion in 2024, reflecting a

Compound Annual Growth Rate CAGR of 21.9%. The market expansion during the historical period can primarily be attributed to the increasing prevalence of cancer, clinical success and approvals of new treatments, strategic collaborations in the field, growing investments in research and development, as well as ongoing market expansion strategies.

“

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to \$24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%”

*The Business Research
Company*

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to \$24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to next-generation adcs, expanding indications,

increasing focus on personalized medicine, rising investment in precision medicine, increasing healthcare awareness. Major trends in the forecast period include advancements in conjugation technologies, improved understanding of tumor biology, technological advancements, expanding therapeutic application, advanced conjugation technologies.

What's Driving This Growth And Projected Expansion?

The primary growth driver for the antibody drug conjugates market is the rising incidence of cancer around the world. Some of the major contributing factors to the increase in cancer cases include obesity, inappropriate eating habits, and the extensive use of tobacco and alcohol. It is forecasted by Cancer Research UK that there will be 27.5 million new cases of cancer each year by 2040. This projected rise in cancer diagnosis rates will propel the demand for antibody-drug conjugates, thus fuelling the market's growth over the forecast period.

Explore Comprehensive Insights Into The Global Antibody Drug Conjugates Market With A Detailed Sample Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp>

Who Are the Key Players In Antibody Drug Conjugates Market?

The comprehensive market report includes numerous major companies operating in the antibody drug conjugates market. These key players include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, and Seagen Inc., among others. Recent advancements and research in the field have given these key players a competitive edge in the marketplace.

What Regulatory Trends Are In Place?

In the United States, manufacturers of antibody-drug conjugates are monitored by various regulatory bodies such as the Food and Drug Administration FDA. But there is currently no specific regulatory guidelines for ADC development in the US. The FDA follows existing guidelines for small molecules and monoclonal antibodies to regulate ADC. The FDA's offices that focus on product quality, like the Office of Biotechnology Products OBP and Office of Pharmaceutical Quality, maintain their focus on the manufacturing of the antibody component of the ADC.

How Is The Market Segmented?

The market for antibody drug conjugates is categorized into several segments:

1 By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types

2 By Product: Adcertis, Kadcyra, Other Products

3 By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology

4 By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications

5 By End User: Hospital, Clinics, Other End Users

Pre-book The Full Report For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report>

How Does The Geographic Distribution Look Like?

In 2023, North America was the largest region for the antibody-drug conjugates ADCs market. During the forecast period, the Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market. This report covers the following regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Oncology Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report>

Convalescent Plasma Therapy Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report>

Dermatology Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at: info@tbrc.info

Stay connected with us on LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/769338725>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.